Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
admitted, advocating, affiliated, appeal, armed, Avenue, aware, Bar, Beaudoin, binding, bought, breach, broadened, brokerage, cancelled, charter, children, concentration, conclusion, concurrent, confirm, consecutive, consequential, contemplated, COO, cumulative, cure, deducting, default, defective, deliberate, delisted, delisting, Destabilized, disabled, discretion, drawn, East, exam, export, fellowship, flow, forecast, formal, freely, freight, gastroenterology, geopolitical, God, half, hearing, Hidden, immaterial, Incentive, inclusion, increasingly, indirect, irrevocable, KDA, legislation, LGBTQ, liabilitie, licensee, Malek, mandatory, Marc, MBA, Middle, MINM, misuse, modification, monitoring, NBND, negligence, Norwalk, notifying, opportunity, outbound, oversee, Panel, paused, PharmaCare, Pharmapar, plant, pool, pose, question, rebound, regain, Robin, robust, safeguard, satellite, Sherbrooke, shipping, singular, SOC, solid, source, specialty, stable, standing, store, stringent, subgroup, submission, suboptimal, suspension, Taurine, terrorist, threat, Titan, tort, TTNP, unreliable, Visible, VP, war, warranty, wholesaler, writing, yielded
Removed:
absence, accruing, annum, assign, attack, auditor, biological, bladder, brain, calcium, cell, colon, commencing, comprehensive, consultant, convert, converted, derivative, desirable, destroy, dispose, distinct, duration, eliminating, embedded, employ, Etoposide, Europe, Figure, hundred, issuing, killing, lender, leukemia, lymphoma, magnitude, marked, markedly, met, mitigation, NOX, nutritional, outbreak, penetrate, penny, pharmacological, pharmacology, Pink, Podophyllotoxin, promulgated, prostate, qualify, reclassification, reclassified, remitting, renewed, repaid, restricted, separately, spread, superior, susceptible, temporary, testicular, thousand, undesignated, unwinding, Vitamin
Financial report summary
?Competition
Bristol-Myers Squibb • Israel • Mylan • Pfizer • AMGEN • Cantaloupe • Astrazeneca • Roche • Novartis • PCTManagement Discussion
- During our fiscal year ended December 31, 2023, we generated revenues of $24,092,787, compared to revenues of $4,345,603 in 2022. The increase was the result of twelve months of Nora Pharma sales included in the 2023 results compared to only seventy-two days of sales in 2022 (October 20, 2022, the date of acquisition of Nora Pharma, through December 31, 2022). The cost of sales in 2023 and 2022 for generating these revenues was $15,753,616 and $2,649,028, respectively.
- General and administrative (“G&A”) expenses for our fiscal year ended December 31, 2023, were $13,124,470, compared to $28,697,325 during our fiscal year ended December 31, 2022, a decrease of $15,572,855. However, excluding the one-time impairment of goodwill in the amount of $18,326,719 from the 2022 G&A expenses, reveals an increase in G&A expenses of $2,753,864 in 2023. This increase is due to G&A expenses incurred by Nora Pharma during all of 2023, compared to only 72 days of G&A expenses included in 2022.
- We had interest income of $811,974 in 2023, compared to interest income of $518,650 in 2022. We incurred $137,308 in interest expense in 2023, compared to $39,412 in interest expense in 2022.